Mobile website
Archive > Volume 24 Issue 3 > 2017,24(3):300-304. DOI:10.3872/j.issn.1007-385X.2017.03.015 Prev Next
Clinical Research
Retrospective analysis of clinical efficacy of CIK cells combined with chemotherapy for the patients with advanced pancreatic cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To analyze retrospectively the clinical efficacy and safety of the cytokine induced killer (CIK) cells combined with chemotherapy for the patients with advanced pancreatic carcinoma. Methods: Twenty eight patients with advanced pancreatic carcinoma who were hospitalized in Department of biotherapy, Tumor Hospital Affiliated to Zhengzhou University during September 2010 to February 2016 were collected. All of the patients received chemical treatment with gemcitabine and/or S-1. CIK cells cultured in vitro were transfused into the patients within 1 to 3 days after the chemotherapy. Rates of progressive disease (PD), stable disease (SD), partial regression (PR) and complete regression (CR), median overall survival ( mOS), rates of survival for 6 months、12 months、18 months and 24 months, disease control rate (DCR) and adverse effects were observed. DCR included CR, PR and SD. Results: Among the 28 patients, PR rate 17.86% (5 cases), SD rate 53.57% (15 cases) and PD rate 28.57% (8 cases) respectively. DCR was 7143%. mOS was 15.41 months. Rates of survival for 6 months、12 months、18 months and 24 months respectively were 85.71%,50.00%,39.28% and 10.71%. The major adverse effects were myelo suppression，nausea and emeses, which were improved after symptomatic treatments. Conclusion: The CIK cells combined with chemotherapy could be an effective and safety treatment approach for the patients with advanced pancreatic carcinoma. The patients might have little adverse reactions and well toleration. The treatment approach could markedly prolong survival of the patients.
Keywords:
Project Supported:
Clc Number:
